RDIF and India’s Stelis Biopharma agreed on partnership to produce Sputnik V

0
130

The Russian Direct Investment Fund (RDIF) and the Indian company Stelis Biopharma have agreed to partner to produce 200 million doses of the Sputnik V vaccine, the fund said.

“RDIF and Stelis Biopharma Pvt. Ltd. (the biopharmaceutical division of Strides, one of the world’s leading pharmaceutical companies headquartered in India), is announcing a partnership for the production and supply of at least 200 million doses of the Russian Sputnik coronavirus vaccine, which will allow the vaccination of 100 million people, “the report said.

The agreement between RDIF and Stelis Biopharma was concluded with the support of Enso Healthcare LLP (a division of Enso Group), an RDIF partner in attracting contract sites for vaccine production in India.

LEAVE A REPLY

Please enter your comment!
Please enter your name here